PRABHU KUMBLE SANDEEP,PAULSON ROBERT FRANK,HEGDE SHAILAJA,KAUSHAL NAVEEN,GANDHI UJJAWAL HITENDRA
申请号：
NZ61937712
公开号：
NZ619377A
申请日:
2012.06.29
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The disclosure relates to a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a first anti-cancer drug consisting of: isolated or synthesized delta12-prostaglandin J3 (delta12-PGJ3 - see abstract drawing) for inhibiting leukaemia stem cell (LSC) growth. The composition may further have a second anti-cancer drug, which may be imatinib. The disclosure also relates to the use of a composition comprising a pharmaceutically acceptable carrier and at least a first anti-cancer drug selected from isolated or synthesized delta12-PGJ3 in a therapeutically effective amount for inducing death of LSCs in the subject thereby treating leukaemia.
